Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
Saved in:
| Title: | Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. |
|---|---|
| Authors: | Wang K; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Du R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Roy-Chowdhuri S; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Li ZT; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong L; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vokes N; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Elamin YY; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hume CB; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Skoulidis F; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gay CM; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Blumenschein G; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fossella FV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tsao A; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang J; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Karachaliou N; The Healthcare Business of Merck KGaA, Darmstadt, Germany., O'Brate A; The Healthcare Business of Merck KGaA, Darmstadt, Germany., Gann CN; The Healthcare Business of Merck KGaA, Darmstadt, Germany., Lewis J; Department of Quantitative Research Computing, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rinsurongkawong W; Department of Quantitative Research Computing, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gibbons DL; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vaporciyan AA; Department of Thoracic & Cardiovasc Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas., Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Altan M; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Le X; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. |
| Source: | JTO clinical and research reports [JTO Clin Res Rep] 2023 Jun 01; Vol. 4 (8), pp. 100533. Date of Electronic Publication: 2023 Jun 01 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37649681 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Wang+K%22">Wang K</searchLink>; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Du+R%22">Du R</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Roy-Chowdhuri+S%22">Roy-Chowdhuri S</searchLink>; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Li+ZT%22">Li ZT</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Hong+L%22">Hong L</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Vokes+N%22">Vokes N</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Elamin+YY%22">Elamin YY</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Hume+CB%22">Hume CB</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Skoulidis+F%22">Skoulidis F</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Gay+CM%22">Gay CM</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Blumenschein+G%22">Blumenschein G</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Fossella+FV%22">Fossella FV</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Tsao+A%22">Tsao A</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Zhang+J%22">Zhang J</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Karachaliou+N%22">Karachaliou N</searchLink>; The Healthcare Business of Merck KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22O'Brate+A%22">O'Brate A</searchLink>; The Healthcare Business of Merck KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Gann+CN%22">Gann CN</searchLink>; The Healthcare Business of Merck KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Lewis+J%22">Lewis J</searchLink>; Department of Quantitative Research Computing, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Rinsurongkawong+W%22">Rinsurongkawong W</searchLink>; Department of Quantitative Research Computing, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Lee+JJ%22">Lee JJ</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Gibbons+DL%22">Gibbons DL</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Vaporciyan+AA%22">Vaporciyan AA</searchLink>; Department of Thoracic & Cardiovasc Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Heymach+JV%22">Heymach JV</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Altan+M%22">Altan M</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Le+X%22">Le X</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101769967%22">JTO clinical and research reports</searchLink> [JTO Clin Res Rep] 2023 Jun 01; Vol. 4 (8), pp. 100533. <i>Date of Electronic Publication: </i>2023 Jun 01 (<i>Print Publication: </i>2023). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101769967 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3643 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663643%22">26663643 </searchLink><i>NLM ISO Abbreviation: </i>JTO Clin Res Rep <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37649681 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.jtocrr.2023.100533 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 100533 Titles: – TitleFull: Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Wang K – PersonEntity: Name: NameFull: Du R – PersonEntity: Name: NameFull: Roy-Chowdhuri S – PersonEntity: Name: NameFull: Li ZT – PersonEntity: Name: NameFull: Hong L – PersonEntity: Name: NameFull: Vokes N – PersonEntity: Name: NameFull: Elamin YY – PersonEntity: Name: NameFull: Hume CB – PersonEntity: Name: NameFull: Skoulidis F – PersonEntity: Name: NameFull: Gay CM – PersonEntity: Name: NameFull: Blumenschein G – PersonEntity: Name: NameFull: Fossella FV – PersonEntity: Name: NameFull: Tsao A – PersonEntity: Name: NameFull: Zhang J – PersonEntity: Name: NameFull: Karachaliou N – PersonEntity: Name: NameFull: O'Brate A – PersonEntity: Name: NameFull: Gann CN – PersonEntity: Name: NameFull: Lewis J – PersonEntity: Name: NameFull: Rinsurongkawong W – PersonEntity: Name: NameFull: Lee JJ – PersonEntity: Name: NameFull: Gibbons DL – PersonEntity: Name: NameFull: Vaporciyan AA – PersonEntity: Name: NameFull: Heymach JV – PersonEntity: Name: NameFull: Altan M – PersonEntity: Name: NameFull: Le X IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2023 Jun 01 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 2666-3643 Numbering: – Type: volume Value: 4 – Type: issue Value: 8 Titles: – TitleFull: JTO clinical and research reports Type: main |
| ResultId | 1 |
